Fulcrum Therapeutics Inc. has granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. The new hires received a total of 30,400 options to purchase company common stock at an exercise price of $10.84 per share, based on the closing price on January 5, 2026. The options have a ten-year term and vest over four years, with 25% vesting after the first year and the remaining shares vesting in equal quarterly installments over the next three years, contingent on continued employment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621116-en) on January 09, 2026, and is solely responsible for the information contained therein.
Comments